Spotting progression in MS: What are you missing?

Dr. Marcello Moccia is Associate Professor at the University of Naples, Italy, and Consultant Neurologist at the Policlinico University Hospital of Naples, Italy. Dr Moccia received his medical degree (MD) from University of Naples in 2010 and completed there his training in Neurology (2016) and PhD in Neuroscience (2019). He has further trained at the National Hospital for Neurology and Neurosurgery from 2015 (London, UK), and has been awarded MD (Res) degree at UCL Queen Square Institute of Neurology (London, UK) (2020). His clinical and research interests are in the field of multiple sclerosis, including immunology, neuroimaging, epidemiology and translational applications. Dr Moccia has authored over 200 peer-reviewed and indexed articles. He is Editorial Board Member of Neurology and Multiple Sclerosis Journal, and touchREVIEWS in Neurology.

Marcello Moccia has nothing to disclose.

Georgina Arrambide, MD, PhD, trained as a neurologist and multiple sclerosis/NMOSD specialist at the National Institute of Neurology and Neurosurgery in Mexico City. She works at the Multiple Sclerosis Centre of Catalonia (Cemcat) in Barcelona, Spain, since 2009. Her main area of research involves the identification of clinical, radiological, and fluid molecular diagnostic and prognostic biomarkers in patients with clinically isolated syndromes (CIS), and the differential diagnosis of MS including NMOSD and MOGAD. She is co-leading the NMOSD and MOGAD clinic at Cemcat since October 2021. She is the editor for Europe of the Multiple Sclerosis Journal – Experimental, Translational and Clinical and a member of the editorial committee of the Acta Neurológica Colombiana. Finally, she is a member of the International Women in Multiple Sclerosis (iWiMS) network executive committee, the European Biomarkers in Multiple Sclerosis (BioMS-eu) steering committee, the MOGAD Eugene Devic European Network (MEDEN) steering group, the Platform Adaptive Trial for remyelination and neuroprotection in mUltiple Sclerosis (PLATYPUS) steering committee, and the CURE-MS steering committee.

Georgina Arrambide has recieved grant/research support from Instituto de Salud Carlos III, grant PI22/01570; is on the advisory board for UCB; has received honoraria/honorarium from Roche, Sanofi, Bristol Myers Squibb, and UCB; and is Editor for Europe of Multiple Sclerosis Journal – Experimental, Translational and Clinical.

Prof. Friedemann Paul is a leading neurologist and neuroimmunologist based at Charité – Universitätsmedizin Berlin, where he serves as Director of the Clinical and Experimental Multiple Sclerosis Research Center and Head of the Clinical Neuroimmunology Group. His research focuses on multiple sclerosis, neuromyelitis optica spectrum disorders and other autoimmune diseases of the central nervous system, with particular expertise in advanced neuroimaging, retinal imaging and biomarker development. Prof. Paul has authored more than 900 peer-reviewed publications and is recognised as a Clarivate Highly Cited Researcher. His work aims to improve diagnosis, disease monitoring and the development of novel therapeutic approaches.

Friedemann Paul is a consultant for Roche, Novartis, Toleris, Amgen, Alexion, Merck, and AptaTherapeutics; has recieved grant/research support from DFG, BMBF, EU IHI, EU Horizon, GJCF, and the following companies: Roche, Novartis, Toleris, Amgen, Alexion, Merck, and AptaTherapeutics; is on the advisory board for Roche, Novartis, Toleris, Amgen, Alexion, Merck, and AptaTherapeutics; and has receoved honoraria/honorarium from Roche, Novartis, Toleris, Amgen, Alexion, Merck, and AptaTherapeutics.

Dr Riley Bove trained in Anthropology at Harvard College, and received her MD and Masters in Translational research from Harvard Medical School. She completed her Neurology residency and Neuroimmunology fellowship at MassGeneral Brigham Hospitals. She transitioned to UCSF in 2015. There she leads a Laboratory focused on women’s neurology and on neurotechnology, and provides comprehensive care for individuals with MS in the UCSF Center for MS and Neuroinflammation.

Ahmed Abdelhak, MD, is an assistant professor and attending physician at the Department of Neurology at the University of California, San Francisco (UCSF). He specializes in care for patients with neuroimmunological conditions. Dr. Abdelhak’s translational Lab focuses on understanding the earliest biological changes in neurological diseases and identifying reliable biomarkers that can predict disease progression and treatment response. His expertise spans assay development, targeted protein detection, and advanced proteomic profiling, aiming to improve our understanding of neuronal injury, enable early diagnosis, and enable personalized treatment strategies for neurological disorders like MS.

Ahmed Abdelhak has received grant/research support from NMSS, NINDS, and DMSG; is on the advisory board for Genentech, Sanofi, and Roche; has receieved honoraria/honorarium from Roche, and Sanofi.